Sponsored by Sica Media*

Hey, here’s something wild before markets close early today. There’s a huge gap between this company’s market cap and its subsidiary’s value, and the stock’s been ripping lately — but not enough! Check it out while it’s still flying under the radar.

TODAY’S TOP ALERT! 

Citius Pharma (Nasdaq: CTXR)

👉  CTXR is TODAY’S #1 ALERT 👈

Good morning, Folks!

All eyes will be on the government’s jobs report this morning as we head into the holiday weekend.

👉 As a reminder, markets close at 1:00 pm today, so get your trades in while you can!

We’ve had a great week of “tactical trade” ideas, with four making double-digit intraday gains, and the fifth was positive on the day.

My last swing of the week is on a stock with tremendous momentum at its back…

It’s up 172% in the last month alone, and with its 10% gain on the day yesterday, it’s showing no signs of slowing down.

Go ahead and pull up Citius Pharmaceuticals Inc (CTXR) right now.

As you can see, the stock pulled back over much of 2025, punctuated by a couple of great runups.

I’m pleased to say I alerted one of them back in March before the stock ran up 40%+ the same day:

At one point, the stock was the #6 mover in the entire market, and its subsidiary CTOR was #3:

The company has had to do a number of capital raises this year, which is typical for biopharma companies that haven’t reached the commercialization stage, though as we’ll see, CTXR is anticipating reaching that imminently.

On June 12, it announced the closing of a sizable $15.8 million direct offering.

With its financing shored up, CTXR stock has taken off since then, climbing 147% into yesterday’s close.

Beyond that, CTXR’s ~92%-owned subsidiary, Citius Oncology (CTOR), has exploded recently. Since the start of June, the stock is up an astronomical 500%.

Clearly, there’s a discrepancy between the CTXR and CTOR market values.

Do the math with me and see what you think…

CTOR’s market cap is over $370 million, implying that CTXR’s equity stake is over $330 million. That figure alone far exceeds CTXR’s entire market cap.

This dynamic means that either CTOR is overvalued or CTXR is priced far below its fair value.

This disconnect creates a very interesting opportunity for traders to consider with CTXR right now.

Back in March, it was a similar ramp-up in CTOR that clued me in to the imminent CTXR spike, and we’re seeing similar things right now.

That’s why I think today could be a big one for CTXR. Dial in to see how this one plays out!

👉  CTXR is TODAY’S #1 ALERT 👈

CTXR itself is a late-stage biopharmaceutical company with a diversified pipeline and several near-term catalysts.

The New Jersey-based company is set to completely transform the standard of care in patients with infections stemming from Central Venous Catheters (CVCs).

If its lead candidate, Mino-Lok, is approved — and that’s looking increasingly likely — it would be the first and only FDA-approved antibiotic lock solution for salvaging CVCs.

That may not sound like the most exciting thing, but it would actually be a really huge deal.

For those who don’t know, CVCs are thin tubes that are inserted into large veins in the chest, neck, or groin.

They’re used to provide patients with medications, fluids, and nutrition, and for regular blood sampling.

Every year, approximately 7 million CVCs are used in the U.S., with 4 million of those being long-term, meaning they are used for longer than a month.

Each year, approximately 500,000 of these catheters get infected, resulting in conditions known as central line-associated bloodstream infection (CLABSI) and catheter-related bloodstream infection (CRBSI).

The standard “cure” for CLABSI/CRBSI is for the patient to take a round of antibiotics and have the CVC removed and replaced.

The problem is it is extremely painful and even traumatizing to remove/replace a CVC, and it can interrupt care for the patient’s underlying condition…

(Many of these patients are extremely vulnerable — undergoing chemotherapy, ICU patients, etc.)

One study found that 57%–67% of patients had adverse physical and psychological symptoms from CVC removal and replacement, with 32% experiencing moderate-to-severe symptoms.

It’s also very expensive — costing about $10,000 — and the overall CLABSI/CRBSI treatment can cost as much as $65,000.

CTXR is hoping to replace this unacceptable standard of care with Mino-Lok, an antibiotic solution intended to actually salvage infected catheters.

Mino-Lok has gone through a complete Phase 3 trial, and the company reported topline results on May 21, noting that it had achieved the primary endpoint and several secondary endpoints with very high statistical significance.

Citius CEO Leonard Mazur said the CTXR is “extremely pleased by the strong results,” and the company held a Type C meeting with the FDA in November that provided CTXR with “clear, constructive, and actionable guidance.”

The company estimates the potential market for Mino-Lok at more than $1 billion in the U.S. and $2 billion globally.

CTXR spun off of a different lead asset, LYMPHIR, into a wholly owned subsidiary named Citius Oncology, and that subsidiary merged with a SPAC in August.

CTXR holds approximately 92% of the combined company, which operates as Citius Oncology, Inc. (CTOR).

A few days prior to the merger, LYMPHIR was approved by the FDA for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).

CTCL is a rare form of non-Hodgkin lymphoma that afflicts roughly 3,000 new people each year, and the overall market for it is estimated at $400 million. 

I don’t need to tell you what a huge deal FDA approval is, and CTXR plans to commercialize LYMPHIR soon.

As part of that, on June 9, the company tapped Cardinal Health, “a leading provider of pharmaceutical and specialty pharmaceutical distribution services,” to distribute LYMPHIR.

CTXR’s third major “shot on goal” is Halo-Lido, “a proprietary topical formulation … that is intended to provide anti-inflammatory and anesthetic relief to individuals suffering from hemorrhoids.”

Halo-Lido had a very positive Phase 2b trial, and Citius is now planning on an end of phase II meeting with the FDA to discuss the next steps in the regulatory and clinical development program.

If all goes well, Halo-Lido would be the first FDA-approved prescription product to treat hemorrhoids, a market Citius estimates at over $2 billion in the U.S. alone.

Citius insiders show strong faith in the company, with co-founder and CEO Leonard Mazur investing $22.5 million of his own money directly into the company, and with co-founder and Executive Vice Chairman Myron Holubiak investing $4 million.

I love companies where management has that type of “skin in the game.” 

Analysts are bullish, too: 

• D. Boral Capital placed to a $6 12-month price target June 10

• H.C. Wainwright reiterated a BUY with a whopping $4 price target on April 14

Those price targets represent potential upsides between 185% and 90% based on yesterday’s closing price.

As you do your own research, be sure to review this investor presentation released just this month as well as the company website.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: CTXR has a strong pipeline that includes its first-ever FDA approval last year. MINO-Lok and Halo-Lido could also transform the standards of care for their indications.

With CTOR (a ~92%-owned subsidiary of CTXR) shares up over 500% since the start of June to a market cap over $370 million, I don’t think CTXR’s stock price has nearly caught up with the dynamic. It clearly has momentum, though, and today could be a huge day.

Stay locked in to CTXR to watch all the fireworks! 🎇

To Your Success,

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull